(Q33581390)

28 July 2017

1 reference

5 November 2020

1 reference

systematic review

1 reference

title

A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma (English)

1 reference

28 July 2017

1 reference

5 November 2020

1 reference

5 November 2020

1 reference

5 November 2020

angiogenesis inhibitor

1 reference

5 November 2020

1 reference

prostate adenocarcinoma

1 reference

1

1 reference

28 July 2017

author name string

Marcos Tobias-Machado

2

1 reference

28 July 2017

Marcos A P Esteves

3

1 reference

28 July 2017

Marília D Senra

4

1 reference

28 July 2017

Marcelo L Wroclawski

5

1 reference

28 July 2017

Fernando L A Fonseca

6

1 reference

28 July 2017

Rodolfo B dos Reis

7

1 reference

28 July 2017

Antônio C L Pompeo

8

1 reference

28 July 2017

Auro Del Giglio

9

1 reference

28 July 2017

language of work or name

1 reference

19 May 2010

5 references

28 July 2017

13 March 2019

24 March 2019

3 April 2019

5 November 2020

5 references

28 July 2017

13 March 2019

24 March 2019

3 April 2019

5 November 2020

10

1 reference

28 July 2017

page(s)

9

1 reference

Creative Commons Attribution 2.0 Generic

28 July 2017

copyright license

4 references

13 March 2019

24 March 2019

3 April 2019

on focus list of Wikimedia project

5 November 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Androgen and prostate cancer: is the hypothesis dead?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Cancer treatment-induced bone loss: pathophysiology and clinical perspectives

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Approach to the prostate cancer patient with bone disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Osteoporosis: a disease in men.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

The impact of osteoporosis in men treated for prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Role of bisphosphonates in prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Hip fracture in elderly men: prognostic factors and outcomes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Prostate cancer diagnosis and management

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Severe Osteoporosis in Men

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Incidence and risk factors for low trauma fractures in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882358

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-9

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer

21 January 2018

1 reference

12 December 2020

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma

1 reference

12 December 2020

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

12 December 2020

Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients

1 reference

12 December 2020

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

1 reference

12 December 2020

Osteoporosis in older men: discovering when and how to treat it

1 reference

12 December 2020

Skeletal fractures negatively correlate with overall survival in men with prostate cancer

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy

1 reference

12 December 2020

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

1 reference

12 December 2020

Low bone mineral density in hormone-naïve men with prostate carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2490-10-9

1 reference

Dimensions Publication ID

28 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2490-10-9

9 September 2019

1 reference

28 July 2017

1 reference